- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04311164
Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes
January 29, 2021 updated by: Signe Schmidt, Steno Diabetes Center Copenhagen
Steno Tech Explore: A Multisite Exploratory Study of People With Type 1 Diabetes on Insulin Pump Therapy
The present study is part of an overarching study being conducted in Denmark at Steno Diabetes Center Copenhagen (SDCC) and Nordsjællands Hospital Hillerød (NOH), Steno Tech, that aims to develop and ultimately, in a randomized controlled trial (RCT), test approaches that can assist people with type 1 diabetes in obtaining optimal outcomes using CSII.
Through a large-scale, questionnaire-based online survey enriched with data from national registers, this sub-study contributes to this overarching aim by exploring the importance of individual differences across a wide range of factors, including demographic, socioeconomic, health status, psychosocial and preference structures, for optimal use of CSII in people with type 1 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
See attached protocol for a detailed description.
Study Type
Observational
Enrollment (Actual)
770
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gentofte, Denmark, 2820
- Steno Diabetes Center Copenhagen
-
Hillerød, Denmark, 3400
- Nordsjællands Hospital Hillerød
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study population consists of two groups/cohorts:
- Steno Tech Survey Respondents: A cohort of individuals with type 1 diabetes treated with CSII at either Steno Diabetes Center Copenhagen or Nordsjaellands Hospital Hilleroed participating in the Steno Tech Survey.
- General Type 1 Diabetes Population: A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).
Description
The Steno Tech Survey Repondents group:
- Adult (18+ years)
- Type 1 diabetes
- Insulin pump user
- Danish-speaking
The General Type 1 Population group:
- Adult (18+ years)
- Type 1 diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Steno Tech Survey Respondents
A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.
|
The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
|
General Type 1 Diabetes Population
A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca.
25.000 individuals).
|
No intervention was given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycated Hemoglobin A1c (HbA1c)
Time Frame: 13 years (from 2008 (beginning of register) to present)
|
Information on HbA1c in mmol/mol will be extracted from national registers
|
13 years (from 2008 (beginning of register) to present)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Other diabetes-relevant biomarkers
Time Frame: 13 years (from 2008 (beginning of register) to present)
|
Biomarkers included at the regular diabetes 'check-up' other than HbA1c including hemoglobin, eGFR, UACR, cholesterol total, HDL, LDL, VLDL, triglycerides and TSH will be extracted from national registers
|
13 years (from 2008 (beginning of register) to present)
|
General diabetes and insulin pump-specific behavior
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with single items in the survey
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Psychological well-being
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with the WHO5 questionnaire scale in the survey
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Diabetes distress
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with the Type 1 Diabetes Distress (T1-DDS) questionnaire scale in the survey
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Hypoglycemia anxiety
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with the Hypoglycemia Fear Survey short-form (HFS-SF) questionnaire scale in the survey
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Technology-specific satisfaction
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with the Insulin Device Satisfaction Survey (IDSS) and the Glucose Monitoring Satisfaction Survey (GMSS) questionnaire scales in the survey
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Educational, time and risk preferences
Time Frame: 1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Measured with single items in the survey and experimental tasks
|
1 day (measured at one time point only, i.e., at the survey completion date for each participant)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2020
Primary Completion (Actual)
October 15, 2020
Study Completion (Actual)
October 15, 2020
Study Registration Dates
First Submitted
March 11, 2020
First Submitted That Met QC Criteria
March 14, 2020
First Posted (Actual)
March 17, 2020
Study Record Updates
Last Update Posted (Actual)
February 1, 2021
Last Update Submitted That Met QC Criteria
January 29, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Steno Tech Explore
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
Clinical Trials on Questionnaire-based survey
-
GlaxoSmithKlineCompleted
-
Cairo UniversityNot yet recruitingTemporomandibular Disorders | Smartphone Addiction
-
Medical University of GrazCompletedHealth Care Utilization | Medication Compliance | Information Seeking BehaviorAustria
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedColorectal Cancer | Familial Adenomatous PolyposisUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedTobacco Use Cessation | Tobacco PreventionUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast CarcinomaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
M.D. Anderson Cancer CenterCompleted
-
Henan University of Traditional Chinese MedicineNot yet recruiting